Integragen (ALINT.PA) Stock Price

Integragen Price

Euronext·CLOSED
0.19EUR-0.02 (-10.69 %)
Market closed

Revenue has compounded at 4.3% per year over the past 18 years to 5.02 M EUR. Integragen's net margin stands at -53.1%, down from 0.1% several years earlier. The stock trades about 45% above its 52-week low.

Integragen stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Integragen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Integragen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Integragen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Integragen Stock Price History
DateIntegragen Price
7/31/20260.19 EUR
7/30/20260.21 EUR
7/29/20260.22 EUR
7/28/20260.19 EUR
7/27/20260.15 EUR
7/24/20260.14 EUR
7/23/20260.14 EUR
7/22/20260.14 EUR
7/21/20260.14 EUR
7/20/20260.14 EUR
7/17/20260.15 EUR
7/15/20260.15 EUR
7/14/20260.15 EUR
7/13/20260.15 EUR
7/10/20260.15 EUR
7/9/20260.15 EUR
7/8/20260.16 EUR
7/7/20260.17 EUR
7/6/20260.17 EUR
7/3/20260.17 EUR
7/2/20260.17 EUR
7/1/20260.17 EUR
6/30/20260.17 EUR
6/29/20260.18 EUR
6/26/20260.19 EUR
6/25/20260.19 EUR
6/24/20260.19 EUR
6/23/20260.19 EUR
6/22/20260.19 EUR
6/19/20260.19 EUR
6/18/20260.19 EUR
6/17/20260.19 EUR
6/16/20260.21 EUR
6/15/20260.25 EUR
6/12/20260.18 EUR
6/11/20260.20 EUR
6/10/20260.20 EUR
6/9/20260.20 EUR
6/8/20260.20 EUR
6/5/20260.19 EUR
6/4/20260.22 EUR
6/3/20260.24 EUR
6/2/20260.25 EUR
6/1/20260.17 EUR
5/29/20260.18 EUR
5/28/20260.19 EUR
5/27/20260.19 EUR
5/26/20260.19 EUR
5/25/20260.19 EUR
5/22/20260.20 EUR
5/21/20260.20 EUR
5/20/20260.21 EUR
5/19/20260.23 EUR
5/18/20260.23 EUR
5/15/20260.23 EUR
5/14/20260.26 EUR
5/13/20260.36 EUR
5/12/20260.27 EUR
5/11/20260.24 EUR
5/8/20260.24 EUR
5/7/20260.17 EUR
5/6/20260.16 EUR
5/5/20260.16 EUR
5/4/20260.17 EUR
4/30/20260.17 EUR
4/29/20260.17 EUR
4/28/20260.17 EUR
4/27/20260.17 EUR
4/24/20260.16 EUR
4/23/20260.17 EUR
4/22/20260.16 EUR
4/21/20260.18 EUR
4/20/20260.19 EUR
4/17/20260.16 EUR
4/16/20260.17 EUR
4/15/20260.18 EUR
4/14/20260.18 EUR
4/13/20260.19 EUR
4/10/20260.19 EUR
4/9/20260.19 EUR
4/8/20260.19 EUR
4/7/20260.19 EUR
4/2/20260.19 EUR
4/1/20260.19 EUR
3/31/20260.19 EUR
3/30/20260.20 EUR
3/27/20260.18 EUR
3/26/20260.18 EUR
3/25/20260.17 EUR
3/24/20260.17 EUR
3/23/20260.15 EUR
3/20/20260.15 EUR
3/19/20260.16 EUR
3/18/20260.16 EUR
3/17/20260.17 EUR
3/16/20260.18 EUR
3/13/20260.17 EUR
3/12/20260.18 EUR
3/11/20260.18 EUR
3/10/20260.18 EUR
3/9/20260.18 EUR
3/6/20260.18 EUR
3/5/20260.18 EUR
3/4/20260.18 EUR
3/3/20260.18 EUR
3/2/20260.17 EUR
2/27/20260.18 EUR
2/26/20260.18 EUR
2/25/20260.18 EUR
2/24/20260.18 EUR
2/23/20260.17 EUR
2/20/20260.16 EUR
2/19/20260.16 EUR
2/18/20260.15 EUR
2/17/20260.17 EUR
2/16/20260.18 EUR
2/13/20260.18 EUR
2/12/20260.18 EUR
2/11/20260.18 EUR
2/10/20260.17 EUR
2/9/20260.19 EUR
2/6/20260.15 EUR
2/5/20260.15 EUR
2/4/20260.15 EUR
2/3/20260.15 EUR
2/2/20260.15 EUR
1/30/20260.15 EUR
1/29/20260.15 EUR
1/28/20260.15 EUR
1/27/20260.16 EUR
1/26/20260.16 EUR
1/23/20260.16 EUR
1/22/20260.16 EUR
1/21/20260.15 EUR
1/20/20260.13 EUR
1/19/20260.13 EUR
1/16/20260.14 EUR
1/15/20260.14 EUR
1/14/20260.14 EUR
1/13/20260.14 EUR
1/12/20260.14 EUR
1/9/20260.14 EUR
1/8/20260.14 EUR
1/7/20260.14 EUR
1/6/20260.14 EUR
1/5/20260.14 EUR
1/2/20260.14 EUR
12/31/20250.13 EUR
12/30/20250.14 EUR
12/29/20250.14 EUR
12/24/20250.14 EUR
12/23/20250.14 EUR
12/22/20250.13 EUR
12/19/20250.14 EUR
12/18/20250.14 EUR
12/17/20250.14 EUR
12/16/20250.14 EUR
12/15/20250.14 EUR
12/12/20250.14 EUR
12/11/20250.14 EUR
12/10/20250.15 EUR
12/9/20250.14 EUR
12/8/20250.17 EUR
12/5/20250.17 EUR
12/4/20250.17 EUR
12/3/20250.16 EUR
12/2/20250.17 EUR
12/1/20250.15 EUR
11/28/20250.15 EUR
11/27/20250.16 EUR
11/26/20250.16 EUR
11/25/20250.17 EUR
11/24/20250.16 EUR
11/21/20250.17 EUR
11/20/20250.13 EUR
11/19/20250.13 EUR
11/18/20250.13 EUR
11/17/20250.13 EUR
11/14/20250.13 EUR
11/13/20250.14 EUR
11/12/20250.14 EUR
11/11/20250.14 EUR
11/10/20250.14 EUR
11/7/20250.14 EUR
11/6/20250.14 EUR
11/5/20250.14 EUR
11/4/20250.14 EUR
11/3/20250.14 EUR
10/31/20250.15 EUR
10/30/20250.15 EUR
10/29/20250.16 EUR
10/28/20250.16 EUR
10/27/20250.16 EUR
10/24/20250.16 EUR
10/23/20250.15 EUR
10/22/20250.15 EUR
10/21/20250.15 EUR
10/20/20250.14 EUR
10/17/20250.14 EUR
10/16/20250.14 EUR
10/15/20250.15 EUR
10/14/20250.15 EUR
10/13/20250.15 EUR
10/10/20250.16 EUR
10/9/20250.16 EUR
10/8/20250.15 EUR
10/7/20250.16 EUR
10/6/20250.15 EUR
10/3/20250.16 EUR
10/2/20250.16 EUR
10/1/20250.16 EUR
9/30/20250.15 EUR
9/29/20250.16 EUR
9/26/20250.16 EUR
9/25/20250.15 EUR
9/24/20250.16 EUR
9/23/20250.16 EUR
9/22/20250.16 EUR
9/19/20250.18 EUR
9/18/20250.18 EUR
9/17/20250.19 EUR
9/16/20250.18 EUR
9/15/20250.18 EUR
9/12/20250.18 EUR
9/11/20250.18 EUR
9/10/20250.18 EUR
9/9/20250.17 EUR
9/8/20250.17 EUR
9/5/20250.17 EUR
9/4/20250.17 EUR
9/3/20250.17 EUR
9/2/20250.17 EUR
9/1/20250.17 EUR
8/29/20250.17 EUR
8/28/20250.18 EUR
8/27/20250.18 EUR
8/26/20250.18 EUR
8/25/20250.18 EUR
8/22/20250.19 EUR
8/21/20250.18 EUR
8/20/20250.19 EUR
8/19/20250.19 EUR
8/18/20250.20 EUR
8/15/20250.20 EUR
8/14/20250.20 EUR
8/13/20250.18 EUR
8/12/20250.18 EUR
8/11/20250.18 EUR
8/8/20250.18 EUR
8/7/20250.18 EUR
8/6/20250.18 EUR
8/5/20250.19 EUR
Access this data via the Eulerpool API
Get Free API Key

Integragen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
12.54 M EUR
-183,765.00 EUR
-171,399.00 EUR
Jan 1, 2024
8.70 M EUR
-807,000.00 EUR
-256,000.00 EUR
Jan 1, 2025
5.02 M EUR
-2.82 M EUR
-2.66 M EUR
Jan 1, 2026 (e)
6.50 M EUR
-835,074.00 EUR
-1.48 M EUR
Jan 1, 2027 (e)
7.30 M EUR
-937,853.00 EUR
-1.61 M EUR
Jan 1, 2028 (e)
10.50 M EUR
-1.35 M EUR
-429,064.42 EUR
Jan 1, 2029 (e)
12.30 M EUR
-1.58 M EUR
-62,898.58 EUR
Jan 1, 2030 (e)
12.20 M EUR
-1.57 M EUR
335,827.00 EUR

Integragen Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 5:33 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
5.006.006.006.008.008.0011.0013.0012.008.005.006.007.0010.0012.0012.00
-16.6720.00––33.33–37.5018.18-7.69-33.33-37.5020.0016.6742.8620.00–
20.0016.6716.6733.3362.50-25.00-18.18-15.38-16.6712.50-40.00-40.00-40.00-40.00-40.00-40.00
1.001.001.002.005.00-2.00-2.00-2.00-2.001.00-2.00-2.40-2.80-4.00-4.80-4.80
-2.00-1.00-1.00-1.00––––––-2.00––-1.00-1.00-1.00
-40.00-16.67-16.67-16.67––––––-40.00––-10.00-8.33-8.33
-1.00-1.00–-1.00––––––-2.00-1.00-1.00–––
–––––––––––-50.00––––
5.075.016.476.456.496.656.636.636.596.726.876.876.876.876.876.87
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Integragen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Integragen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Integragen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Integragen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Integragen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Integragen stock margins

The Integragen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Integragen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Integragen.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
0.39 %
-0.26 %
0.14 %
Jan 1, 2022
-0.05 %
-1.06 %
-0.03 %
Jan 1, 2023
-0.06 %
-1.47 %
-1.37 %
Jan 1, 2024
20.53 %
-9.28 %
-2.94 %
Jan 1, 2025
-47.22 %
-56.21 %
-53.06 %
Jan 1, 2026 (e)
-47.22 %
-12.85 %
-22.71 %
Jan 1, 2027 (e)
-47.22 %
-12.85 %
-22.00 %
Jan 1, 2028 (e)
-47.22 %
-12.85 %
-4.09 %

Integragen Stock Revenue, EBIT, Earnings per Share

The Integragen earnings per share therefore indicates how much revenue Integragen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.71 EUR
-0.00 EUR
0.00 EUR
Jan 1, 2022
1.99 EUR
-0.02 EUR
-0.00 EUR
Jan 1, 2023
1.90 EUR
-0.03 EUR
-0.03 EUR
Jan 1, 2024
1.29 EUR
-0.12 EUR
-0.04 EUR
Jan 1, 2025
0.73 EUR
-0.41 EUR
-0.39 EUR
Jan 1, 2026 (e)
0.97 EUR
-0.12 EUR
-0.22 EUR
Jan 1, 2027 (e)
1.08 EUR
-0.14 EUR
-0.24 EUR
Jan 1, 2028 (e)
1.56 EUR
-0.20 EUR
-0.06 EUR

Integragen business model & stock analysis

IntegraGen SA is a French biotechnology company based in Evry. It was founded in 2000 and is one of the leading companies in developing commercial applications in genomics and biology. The business model of IntegraGen SA consists of providing solutions and services for the diagnosis and treatment of various diseases, such as cancer, neurodegenerative diseases, and other genetically related diseases. The company is divided into two main areas: Diagnostics and Genomics. The Diagnostics area offers a wide range of services to its customers, including an oncology platform for the diagnosis and prediction of cancer using exclusive biomarker sets. Other diagnostic tests are used for the identification of microorganisms in clinical samples and the detection of autoimmune diseases. In the Genomics area, the focus is on the development and sale of PCR kits for genotyping single nucleotide polymorphisms (SNPs) and analysis kits for RNA expression. These solutions allow for the identification and validation of genes in specific biological samples in a way that improves customers' understanding and enables accurate findings. IntegraGen SA is committed to continuously developing new tests and platforms to help its customers achieve more precise diagnoses and better therapies. One notable development of the company is the screening kit "Arisk," which is specifically designed for identifying genotypes that have an increased risk of colorectal cancer. The screening kit uses specific SNPs to ensure that doctors can identify patients who require increased monitoring or even prophylactic surgery. The use of genomics technology and biomarker-based diagnostics is a growing trend in medicine. IntegraGen SA plays a significant role in enabling the integration of genomics into clinical practice, ensuring the best possible diagnosis and treatment for patients. In summary, IntegraGen SA is an innovative biotechnology company dedicated to providing solutions for the diagnosis and prevention of diseases using various technologies. The company is constantly striving to develop new products and services to provide customers and partners with the best possible diagnostic and therapeutic support.

Integragen SWOT Analysis

Strengths

Integragen SA possesses several strengths that contribute to its competitive advantage:

  • Strong Research and Development (R&D) capabilities
  • Advanced and innovative technology
  • Skilled and experienced workforce

Weaknesses

Despite its strengths, Integragen SA also faces certain weaknesses:

  • Dependence on a limited number of key clients
  • Relatively small market share
  • Financial dependency on external funding

Opportunities

Integragen SA can leverage the following opportunities to drive growth:

  • Expanding into new geographic markets
  • Contacting strategic partnerships and collaborations
  • Increasing demand for personalized medicine

Threats

Integragen SA must be aware of the following threats that could impact its business:

  • Intense competition in the genomics industry
  • Regulatory hurdles and compliance requirements
  • Economic downturns and market volatility

Integragen Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Integragen historical P/E ratio, EBIT multiple, and P/S ratio

Integragen annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Integragen shares outstanding

The number of shares of Integragen was 6.87 M in 2025. This indicates how many shares Integragen is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
6.63 M Stocks
Jan 1, 2022
6.63 M Stocks
Jan 1, 2023
6.59 M Stocks
Jan 1, 2024
6.72 M Stocks
Jan 1, 2025
6.87 M Stocks
Jan 1, 2026 (e)
6.87 M Stocks
Jan 1, 2027 (e)
6.87 M Stocks
Jan 1, 2028 (e)
6.87 M Stocks
Price targets and forecasts for Integragen are not yet available.

Integragen shareholder structure

% Name
65.86881%
Oncodna SA
Oncodna SA

Integragen Beneficial Ownership Filings (SEC 13D/G)

Free Float
33.8%
Float Shares
-
Shares Outstanding
-

Integragen Executives and Management Board

10 members · 10 % women

Management

BC

Mr. Bernard Courtieu

Chief Executive Officer · since 2007

–
EM

Mr. Emmanuel Martin

Chief Operating Officer, Member of the Management committee

–
BG

Mr. Berengere Genin

Member of the Management committee, Head of Academics, Research & Hospitals Business unit · since 2020

–
LD

Mr. Louis-victor Delouvrier

Investor Relations, Financial Communications · since 2022

–

Board of Directors

JS

Mr. Jean Stephenne

Chairman of the Board

–
PF

Mr. Pierre Flamant

Administrative and Finance Director, Member of the Management committee

–
CD

Mrs. Catherine David

Member of the Management committee, Quality Director

–
LY

Mr. Larry Yost

Member of the Management committee, Director of the American subsidiary IntegraGen, Inc. · since 2014

–
AD

Mr. Alain Declercq

Director

–
JD

Mr. Jean-pol Detiffe

Director

–

Frequently asked questions about Integragen

Integragen SA is a leading company specializing in innovative genomic services and molecular diagnostics. Their business model revolves around providing personalized healthcare solutions through cutting-edge genetic analysis and bioinformatics. By leveraging their expertise in advanced sequencing technologies, Integragen offers accurate and reliable genetic testing services to improve patient care. They prioritize collaboration with healthcare professionals and researchers to deliver customized genomic insights for a range of applications, including cancer diagnostics, rare diseases, and pharmacogenomics. Integragen SA's commitment to leveraging genomics for better health outcomes makes them an esteemed player in the field of precision medicine.

Integragen SA is primarily active in the field of genetic sequencing and molecular diagnostics for cancer and autism. This French biotechnology company specializes in providing innovative solutions and services to healthcare professionals and researchers. With its cutting-edge technology and expertise in genomics, Integragen SA aims to improve patient care and advance scientific discoveries in these critical areas.

The main competitors of Integragen SA in the market include Genomic Health Inc., Foundation Medicine Inc., and Veracyte Inc.

Integragen SA, founded in 2000, is a leading biotechnology company specializing in genomic solutions for personalized medicine. Headquartered in France, the company focuses on the development and implementation of advanced genomic testing methods. With a strong background in genetic research, Integragen SA offers comprehensive molecular diagnostics and innovative solutions for disease management. Its expertise lies in genetic sequencing, bioinformatics, and data analysis, enabling it to provide personalized insights into various medical conditions. Integragen SA's commitment to revolutionizing healthcare through genomics has established it as a trusted partner in the advancement of personalized medicine.

Integragen SA, a leading company in the field of genomics, has achieved numerous significant milestones. One notable achievement is their development of innovative genomic solutions, catering to the needs of both academic researchers and healthcare professionals. By leveraging their advanced technology and expertise, Integragen SA has successfully provided high-quality genomic sequencing and analysis services to various institutions and organizations. Additionally, the company has made significant contributions to the development of personalized medicine, allowing for better understanding and treatment of complex diseases. Integragen SA's commitment to excellence and continual innovation has positioned them as a prominent player in the genomics industry, driving advancements in healthcare and research.

Integragen SA is primarily present in France, the United States, and Belgium.

Integragen SA represents strong values and a unique corporate philosophy. With a focus on innovation and scientific excellence, Integragen SA constantly strives to provide cutting-edge genetic solutions to its clients. The company's commitment to quality and precision enables them to offer personalized healthcare and diagnostic services, catering to the individual needs of each patient. Integragen SA prioritizes ethical practices and values collaboration, fostering partnerships with leading research institutions and healthcare providers. By harnessing the power of genomics, Integragen SA aims to improve patient outcomes and contribute to the advancement of precision medicine.

9 analysts currently rate the Integragen stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Integragen to generate revenue of 6.50 M EUR and earnings per share of -0.21 EUR.

Integragen Analyst Price Targets 2026

The Integragen share (ALINT.PA) is listed on 2 stock exchanges, including: Paris (ALINT.PA).

Integragen SA is a company specialized in the development and sale of genetic tests and data analysis. The company was founded in 2000 and is headquartered in Evry, France. Its core business is DNA sequencing and analysis, conducting genome studies, pharmacogenomics, biomarker development, precise diagnostics, and personalized medicine. Integragen has three core divisions: Biopharmaceuticals, Medical Genomics, and Research Support. It offers services to support biotech and pharmaceutical companies in developing personalized medicines, assists healthcare professionals in identifying genetic changes in patients, and provides comprehensive genomics services for genetic research. The company also offers various genetic tests for cancer prevention and diagnosis, assessing the risk of cardiovascular diseases, and grouping metabolism processes. Integragen has a wide network of partners in the biotech and pharmaceutical industry, as well as academia, and aims to expand its business through strategic partnerships and acquisitions. In summary, Integragen is a leading company in the genomics industry with a wide range of services and products, focusing on personalized medicine and genetic research to drive growth in the coming years.

The expected revenue of Integragen is 6.50 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Integragen is -1.48 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Integragen is currently -0.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Integragen stock.

The price-to-sales ratio (P/S) of Integragen is currently 0.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Integragen stock.

The Eulerpool Quality Score for Integragen is 2/10.

The ISIN of Integragen is FR0010908723. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Integragen is A1J1JV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Integragen is ALINT.PA. The ticker symbol is used to trade Integragen shares on the stock exchange.

Integragen paid dividends every year for the past 0 years.

Integragen is assigned to the 'Health' sector.

The dividends of Integragen are distributed in EUR.

All fundamentals and in-depth analysis of Integragen

Our stock analysis for Integragen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integragen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Integragen Stock
Integragen Revenue→
Integragen Stock
Integragen Net Income→
Integragen Stock
Integragen P/E→
Integragen Stock
Integragen P/S→
Integragen Stock
Integragen EBIT→
Integragen Stock
Integragen Dividend→
Integragen Stock
Integragen Directors Dealings→
Integragen Stock
Integragen Stocks→
Integragen Stock
Integragen Market capitalization→
Integragen Stock
Integragen Debt→
Integragen Stock
Integragen Liabilities→
Integragen Stock
Integragen Equity→
Integragen Stock
Integragen AAQS→
Integragen Stock
Integragen Employees→
Integragen Stock
Integragen ROE→
Integragen Stock
Integragen ROA→
Integragen Stock
Integragen ROCE→
Integragen Stock
Integragen News→
Integragen Stock
Integragen Analyst Price Targets→

Health Stocks

Integral DiagnosticsIntegra Lifesciences HoldingsIntegrated Diagnostics HoldingsInteger HoldingsIntegrumIntech BiopharmIntelicare HoldingsIntco Medical Technology CoIntellia TherapeuticsIntai TechnologyIntelligent Bio SolutionsInsuletAll Stocks A–Z →